5/22/2003 4:48:26 PM ET


    Global Path/Swiss Medica Announces New Senior Management Team
      
    TORONTO, May 22, 2003 /PRNewswire-FirstCall via COMTEX/ --
    Raghu Kilambi, Chairman and CEO of Global Path Inc. (OTC Bulletin Board: GBPI), renamed Swiss Medica, Inc.
    effective June 20, 2003 (see May 20, 2003 press release), is pleased to announce the appointment of his new
    senior management team.

    Effective immediately, Grant Johnson joins Swiss Medica as President and COO. Johnson will lead Swiss
    Medica's drive to market. Johnson is a seasoned executive with over 19 years of broad business experience and
    a strong track record in selling consumer products and services. As CEO of Healthnet International, Johnson
    grew the company to an $85 million market cap by forging strong relationships with important healthcare industry
    players such as GNC and MotherNature.com.

    Johnson stated, 'Over the last several months my team and I have had the opportunity to use Swiss Medica's
    biosciences products and the results we have personally experienced have helped make it an easy decision to
    join the Swiss Medica team. We are well positioned with over 60 years of collective experience and relationships
    to move these products to market very quickly and we expect an overwhelming response.'

    Greg Nuttall will be joining Swiss Medica as Vice-Chairman, Corporate Strategy and Business Development.
    Nuttall will lead Swiss Medica's acquisition and business development initiatives, along with playing a key overall
    strategic role. Nuttall is an experienced business builder and merchant banker, is a principal of Rubicon
    Investment Group, was CEO of a leading change management consulting firm with customers such as
    healthcare giant Pfizer Consumer Health, and was formerly an M&A and corporate finance lawyer practicing at
    two of the world's top law firms. Nuttall has a B.A., an LL.B., and earned his Master of International Laws degree
    at Cambridge University in England.

    Nuttall commented, 'Swiss Medica's products are startlingly effective and have the potential to lead a rapidly
    growing market. The biosciences field is highly fragmented and there is a tremendous opportunity for Swiss
    Medica to take the lead in the industry through selective acquisition of the best products and powerful strategic
    marketing relationships. I have tremendous respect for the people involved in Swiss Medica, and I look forward
    to helping our team capitalize on this attractive growth opportunity.'

    Johnson will be bringing with him a team of sales and marketing veterans in the health and biosciences sector.

    Michael Bain will join Swiss Medica in the role of Vice-President, Sales and Marketing. Bain has extensive
    knowledge of the mass-market beginning with close ties to several major retail chains. He has held key positions
    in sales, marketing, costing, and strategic advertising approaches for a number of companies within the natural
    products industry. Bain is also the founder of Rainmaker beverages.

    Robert Klein joins Swiss Medica as Vice-President, Strategic Planning and Budgeting. Klein is an experienced
    consultant and former stock analyst with strong strategic planning and research skills. Klein has helped
    numerous companies attain their goals by raising capital, providing market research and building financial
    models.

    David Wolsey will be joining as General Manager of E-Commerce Operations. Wolsey brings over 20 years of
    experience in consumer and packaged goods and is an experienced e-commerce and retail business builder
    with significant online health product sales experience. Over the course of his career, Wolsey has been involved
    in marketing over 15,000 different health and beauty products.

    Kilambi had this to say about his new senior management team: 'I am delighted and proud that such an
    exceptional group of individuals has chosen to join Swiss Medica and help bring the company's uniquely
    effective biosciences products to the consumer. With deep expertise in marketing, selling and acquiring
    consumer health care products, my new team has all the skills we need to take full advantage of the massive
    and growing biosciences market.'

    About Swiss Medica Inc.

    Swiss Medica Inc. is focused on acquiring over-the-counter bioscience products with demonstrated competitive
    advantages and increasing their revenues by focused sales and marketing efforts in selected distribution
    channels including direct sales, direct response, and e-commerce. Swiss Medica's mission is to be a world
    leader in the acquisition and commercialization of life-enhancing bioscience products that improve quality of lives.

    Forward-looking statements in this news release are made pursuant to the 'Safe Harbor'provisions of the United
    States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's services, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    SOURCE Swiss Medica, Inc.